Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating Officer
March 05 2020 - 6:00AM
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage
biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders, today
announced the appointment of Mark Jacobson as Chief Operating
Officer. In this new role, Mr. Jacobson will oversee the day-to-day
operations of the company, including aspects of research and
development, manufacturing, program management, and corporate
development.
“I am delighted to announce the promotion of
Mark which recognizes his exceptional leadership and
results-oriented approach, making him the ideal person to lead
operations for Axsome through what we believe to be a
transformational time,” said Herriot Tabuteau, MD, Chief Executive
Officer of Axsome. “Since joining Axsome as its second employee,
Mark has been instrumental in the rapid growth of the company and
the achievement of multiple important corporate milestones. Today's
announcement reflects the continued expansion of our organization
as we evolve into a premier, fully integrated biopharmaceutical
company developing and commercializing differentiated medicines for
patients living with serious and difficult-to-treat CNS
disorders.”
Mr. Jacobson has been a member of the Axsome
team since April 2014, and has served as our Senior Vice President,
Operations since September 2017. Prior to joining Axsome, he was
Director of Corporate Development at Stemline Therapeutics, Inc.,
where his responsibilities covered corporate operations, investor
relations, public relations, and intellectual property. Mr.
Jacobson began his career in healthcare communications at Publicis
Healthcare Communications Group. Mr. Jacobson earned a Master of
Arts in Biotechnology from Columbia University and a Bachelor of
Science in Biology from Iowa State University.
About Axsome Therapeutics,
Inc.
Axsome Therapeutics, Inc. is a clinical-stage
biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders for which
there are limited treatment options. Axsome’s core CNS product
candidate portfolio includes five clinical-stage candidates,
AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is currently in
a Phase 3 trial in treatment resistant depression (TRD), a Phase
2/3 trial in agitation associated with Alzheimer’s disease (AD),
and is being developed for major depressive disorder (MDD). AXS-05
is also being developed for smoking cessation treatment. AXS-07 is
currently in a Phase 3 trial for the acute treatment of migraine.
AXS-12 is being developed for the treatment of narcolepsy. AXS-14
is being developed for the treatment of fibromyalgia. AXS-05,
AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug
products not approved by the FDA. For more information, please
visit the Company’s website at axsome.com. The Company may
occasionally disseminate material, nonpublic information on the
company website.
Forward Looking Statements
Certain matters discussed in this press release
are “forward-looking statements”. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. In particular, the Company’s statements
regarding trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the
success, timing and cost of our ongoing clinical trials and
anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation, pace of
enrollment and completion of the trials (including our ability to
fully fund our disclosed clinical trials, which assumes no material
changes to our currently projected expenses), futility analyses and
receipt of interim results, which are not necessarily indicative of
the final results of our ongoing clinical trials, and the number or
type of studies or nature of results necessary to support the
filing of a new drug application (“NDA”) for any of our current
product candidates; our ability to fund additional clinical trials
to continue the advancement of our product candidates; the timing
of and our ability to obtain and maintain U.S. Food and Drug
Administration (“FDA”) or other regulatory authority approval of,
or other action with respect to, our product candidates (including,
but not limited to, FDA’s agreement with the Company’s plan to
discontinue the bupropion treatment arm of the ADVANCE-1 study in
accordance with the independent data monitoring committee’s
recommendations); the potential for the MOMENTUM clinical trial to
provide a basis for approval of AXS-07 for the acute treatment of
migraine in adults with or without aura, pursuant to our special
protocol assessment; the potential for the ASCEND clinical trial,
combined with the GEMINI clinical trial results, to provide a basis
for approval of AXS-05 for the treatment of major depressive
disorder and accelerate its development timeline and commercial
path to patients; the Company’s ability to successfully defend its
intellectual property or obtain the necessary licenses at a cost
acceptable to the Company, if at all; the successful implementation
of the Company’s research and development programs and
collaborations; the success of the Company’s license agreements;
the acceptance by the market of the Company’s product candidates,
if approved; the Company’s anticipated capital requirements,
including the Company’s anticipated cash runway; and other factors,
including general economic conditions and regulatory developments,
not within the Company’s control. The factors discussed herein
could cause actual results and developments to be materially
different from those expressed in or implied by such statements.
The forward-looking statements are made only as of the date of this
press release and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstance.
Axsome Contact: Mark Jacobson Chief Operating
Officer Axsome Therapeutics, Inc. 200 Broadway, 3rd Floor New York,
NY 10038 Tel: 212-332-3243 Email: mjacobson@axsome.com
www.axsome.com
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Apr 2024 to May 2024
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From May 2023 to May 2024